Lyndon Jones, PhD, DSc, FCOptom, IMI Committee Chair
Centre for Ocular Research & Education (CORE), School of Optometry & Vision Science, University of Waterloo, Canada
Undertaking MC treatment in minors creates an ethical challenge for a wide variety of stakeholders. Regulatory bodies, manufacturers, academics, and clinicians all share an ethical responsibility to ensure that the products used for MC are safe and efficacious and that patients understand the benefits and potential risks of such products.
To discuss guidelines and ethical considerations associated with the development and prescription of treatments intended for myopia control (MC).
Critical review of published papers and guidance documents was undertaken, with a view to carefully considering the ethical standards associated with the investigation, development, registration, marketing, prescription, and use of MC treatments.
The roles and responsibilities of regulatory bodies, manufacturers, academics, eyecare practitioners, and patients in the use of MC treatments are explored.
Particular attention is given to the ethical considerations for deciding whether to implement a MC strategy and how to implement this within a clinical trial or practice setting.
Finally, the responsibilities in marketing, support, and education required to transfer required knowledge and skills to eyecare practitioners and academics are discussed.
This International Myopia Institute report highlights these ethical challenges and provides stakeholders with recommendations and guidelines in the development, financial support, prescribing, and advertising of such treatments.
Keywords: conflict of interest, ethical prescribing, informed consent, medical device, myopia control
Translated versions of IMI clinical summaries are available at myopiainstitute.org
The publication costs of the International Myopia Institute reports were supported by donations from BHVI, Carl Zeiss Vision, CooperVision, Essilor, Alcon, and Vision Impact Institute.
Brien Holden Vision Institute (BHVI) is not-for-profit research & development organisation working in the ophthalmic space. It is a company limited by guarantee, incorporated in Australia. It is regulated by the Australian Charities and Not-for-profits Commission (ACNC).
The assets and income of BHVI are applied solely towards the promotion and furtherance of the objects of the Company as set out in its constitution.
Copyright © Brien Holden Vision Institute (ABN 49 081 303 282). All Rights Reserved.